Safety and Efficacy of Nab-PACLITAXEL (ABRAXANE) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (ABOUND.70+)

Trial Profile

Safety and Efficacy of Nab-PACLITAXEL (ABRAXANE) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (ABOUND.70+)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms ABOUND 70+
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 02 Jun 2017 Interim results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Dec 2016 Interim results (n=128) published in the Celgene Corporation Media Release
    • 28 Oct 2016 According to a Celgene Corporation media release, data from this study is expected to be presented at the IASLC World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top